StreetInsider.com News Articles

Allergan Aesthetics Unveils the Layered Beauty Report, Advancing the Global Conversation Around Aesthetic Care

Wed, 02 Sep 2026 08:00:00 -0400

Building on insights from the U.S. Aesthetics Evolution series, including What Consumers Really Want, new global report explores evolving consumer attitudes toward beauty and aesthetic treatments

NORTH CHICAGO, Ill., Sept. 2, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, today unveiled the Layered Beauty: The New Aesthetic Mindset report, informed by research among more than 12,000 beauty-involved consumers across nine global markets, complemented by practitioner expertise and regional perspectives. The report provides a global perspective on the impact of cultural attitudes toward beauty and aging to evolve the aesthetic treatment

Allergan Aesthetics Unveils the Layered Beauty Report, Advancing the Global Conversation Around Aesthetic Care

Wed, 02 Sep 2026 08:00:00 -0400

Building on insights from the U.S. Aesthetics Evolution series, including What Consumers Really Want, new global report explores evolving consumer attitudes toward beauty and aesthetic treatments

SkinMedica® Adds Barrier Calming Cream to its Collection of Regenerative Skincare Offerings

Tue, 01 Sep 2026 08:05:00 -0400

In clinical testing, Barrier Calming Cream improved skin barrier support and reduced skin dryness by 30% after just two weeks¹
SkinMedica^® also introduces HA^5® Hydra Collagen Facial Mist for easy, on-the-go hydration

IRVINE, Calif., Sept. 1, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), expands SkinMedica's portfolio of regenerative skincare products with the launch of Barrier Calming Cream. The restorative moisturizer is designed to soothe skin while helping restore and fortify the delicate skin barrier.

SkinMedica® Adds Barrier Calming Cream to its Collection of Regenerative Skincare Offerings

Tue, 01 Sep 2026 08:05:00 -0400

In clinical testing, Barrier Calming Cream improved skin barrier support and reduced skin dryness by 30% after just two weeks¹
SkinMedica^® also introduces HA^5® Hydra Collagen Facial Mist for easy, on-the-go hydration

AbbVie to Present at the Wells Fargo 21st Annual Healthcare Conference

Mon, 31 Aug 2026 08:00:00 -0400

NORTH CHICAGO, Ill., Aug. 31, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026. Management will participate in a fireside chat at 9:15 a.m. Central time.

A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the

AbbVie to Present at the Wells Fargo 21st Annual Healthcare Conference

Mon, 31 Aug 2026 08:00:00 -0400

A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the

AbbVie seeks EMA approval for Skyrizi subcutaneous use in Crohn's

Thu, 27 Aug 2026 06:00:26 -0400

AbbVie (NYSE: ABBV) has submitted an application to the European Medicines Agency (EMA) seeking approval for Skyrizi (risankizumab) as a subcutaneous (SC) induction treatment for adults with moderately to severely active Crohn's disease.

The submission is supported by data from the Phase 3 AFFIRM study (NCT06063967), a randomized, placebo-controlled, double-blind trial evaluating the efficacy and safety of risankizumab SC as an induction treatment. The study enrolled 289 patients randomized in a 2:1 ratio to risankizumab SC or placebo, with co-primary endpoints of clinical remission and endoscopic response at week 12. Approximately 65% of patients had previously failed advanced therapies.

Skyrizi is already

AbbVie seeks EMA approval for Skyrizi subcutaneous use in Crohn's

Thu, 27 Aug 2026 06:00:26 -0400

Skyrizi is already

AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

Thu, 27 Aug 2026 02:00:00 -0400

Submission supported by data from Phase 3 pivotal AFFIRM study
If approved, adult Crohn's disease patients will have an additional option for induction of risankizumab which is already approved for intravenous (IV) induction

NORTH CHICAGO, Ill., Aug. 27, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has submitted an application to the European Medicines Agency (EMA) seeking approval for SKYRIZI^® (risankizumab) for subcutaneous (SC) induction for the treatment of adult patients with moderately to severely active Crohn's disease (CD).